Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
56.21
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment
December 15, 2023
Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium
Via
Benzinga
3 Stocks to Buy Before 2024 That Can Set You Up For Life
December 14, 2023
These stocks are still relatively cheap, but don't expect them to stay that way for long.
Via
The Motley Fool
French Pharma Giant Sanofi Drops Rare Disease Drug Pact As Federal Trade Commission Puts Antitrust Obstacle
December 12, 2023
Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic disorder after the Federal Trade Commission (FTC)
Via
Benzinga
Why NASDAQ:SNY provides a good dividend, while having solid fundamentals.
December 12, 2023
Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals.
Via
Chartmill
Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company
December 07, 2023
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S.
Via
Benzinga
How Is The Market Feeling About Sanofi?
November 30, 2023
Via
Benzinga
Is NASDAQ:SNY a Good Fit for Dividend Investing?
November 21, 2023
Is SANOFI-ADR (NASDAQ:SNY) a Good Fit for Dividend Investing?
Via
Chartmill
Looking Into Sanofi's Recent Short Interest
November 13, 2023
Via
Benzinga
This Stock Just Dropped By 15%: Is It a Buy?
November 03, 2023
Now could be a great opportunity to buy low.
Via
The Motley Fool
Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities
December 07, 2023
Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbus
Via
Benzinga
IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies
December 06, 2023
IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and treating autoimmune diseases using IgM...
Via
Benzinga
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
December 06, 2023
Merck KGaA (OTC: MKGAF) (OTC:
Via
Benzinga
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag.
December 06, 2023
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift
December 05, 2023
Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.
Via
Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
December 01, 2023
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies...
Via
Benzinga
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
November 30, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
November 30, 2023
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
Via
The Motley Fool
Teva Pharma is the way to play the re-rise of generic drugs
November 28, 2023
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth
Via
MarketBeat
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
November 27, 2023
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation.
Via
Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
November 27, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that...
Via
Benzinga
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
November 27, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
November 22, 2023
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the
Via
Benzinga
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges
November 17, 2023
The U.S.
Via
Benzinga
Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B
November 16, 2023
Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over...
Via
Benzinga
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag.
November 15, 2023
SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals.
Via
Chartmill
MarketBeat Week in Review – 11/6 - 11/10
November 11, 2023
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Pfizer and Sanofi shares fall, which one to scoop up?
November 07, 2023
Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows
Via
MarketBeat
Exposures
COVID-19
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
November 06, 2023
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases.
Via
Investor's Business Daily
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
November 01, 2023
Via
Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
November 01, 2023
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END
Via
FinancialNewsMedia
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.